Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

3 papers

Anxiety

Based on 52 papers

Research points to two clear groups of treatments for anxiety. First, ordinary approaches like exercise — especially walking and other regular physical activity — have strong, high-quality evidence showing medium-sized reductions in anxiety symptoms. These are proven in many randomized trials and reviews. Second, newer substance-assisted therapies (often called psychedelic‑assisted therapy) are promising. Small clinical trials and reviews show reductions in anxiety and related problems after carefully supervised doses of drugs such as psilocybin, MDMA, ketamine, and ayahuasca. However, these drug approaches are mostly early-stage or done in special research settings and need more, larger trials before they can become routine care. People thinking about or treating anxiety should know that drug‑assisted therapies are almost always given together with serious psychological support. How the drug is given, the preparation before it, and follow-up therapy matter a lot. There are also safety and equity issues to watch: some psychedelics can have rare lasting side effects, many studies are small, and people of color have been underrepresented in trials. For now, exercise has the clearest and broadest evidence. Other treatments are promising but still need more testing and careful medical oversight.

Key findings

  • Many high-quality reviews find regular physical activity reduces anxiety by a medium amount across many trials. 8792
  • Walking specifically lowers anxiety symptoms compared with doing nothing, based on 26 randomized trials pooled together. 8785
  • Clinical trials and reviews report that psychedelic-assisted therapies (drugs given with therapy) reduced anxiety symptoms in people diagnosed with anxiety disorders. 15068 15063 15056
  • For post‑traumatic stress disorder (a trauma-related anxiety condition), MDMA given with psychotherapy produced large benefits in several controlled trials. 15063
  • Psychedelic drugs appear to change the brain in ways that could help anxiety and mood problems. Lab and imaging studies report increased brain plasticity (the brain’s ability to form new connections) and changes in inflammation and brain networks after substances like psilocybin, DMT, and other psychedelics. 15132 15050 15091 15135
  • Ketamine produces fast antidepressant effects and has been tested as an alternative to electroconvulsive therapy; it has also been studied for anxiety-related conditions in some trials. 10149 10160 15068
  • Most studies of psilocybin and other classic psychedelics are small and done with close medical and psychological support, so experts say larger, well‑controlled trials are still needed before routine use. 15056 15078
  • How people are prepared and supported matters a lot: many guides and reviews agree that screening, setting expectations, building trust, and follow‑up therapy are core parts of substance‑assisted psychotherapy. 15065 15092 15063
  • People of color were underrepresented in many psychedelic-assisted psychotherapy studies, which limits how well the results apply to different ethnic groups. 15095
  • There are risks to be aware of: rare but long-lasting perceptual problems (called HPPD) and other psychological or physical side effects have been reported after hallucinogen use, so safety monitoring is important. 15048 15087

Legal highs: staying on top of the flood of novel psychoactive substances

David Baumeister, Luis M. Tojo, Derek K. Tracy

This review explains the fast-growing problem of so-called "legal highs", which are better called novel psychoactive substances or NPS. Unknown labs keep making slightly different chemicals to avoid bans, and this led to about 80 new substances being spotted in one year. The paper groups these drugs into five main…

Forensic Toxicology and Drug Analysis Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Cannabis Ketamine

Psychedelic therapeutics in psychiatric conditions

Philip D. Harvey, Charles B. Nemeroff
Neuropsychopharmacology Summary & key facts 2026 1 citation

Researchers reviewed the fast-growing interest in psychedelic therapies. They found that even though hundreds of studies are under way, no psychedelic medicine is officially approved for any mental health condition yet. The review explains the kinds of drugs being tested, the conditions people hope to treat, and big challenges such…

Diverse academic research themes Forensic Toxicology and Drug Analysis Psychedelics and Drug Studies LSD MDMA

Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind

Alice Melani, Giorgia Papini, Marco Bonaso, Letizia Biso, Shivakumar Kolachalam, Nicola Luigi Bragazzi, et al.
Biomedicines Summary & key facts 2026 0 citations

This paper reviews research on ayahuasca and its main ingredient, DMT, and how they might help with mental health. Ayahuasca is a plant brew that makes DMT work when you drink it because it also contains chemicals that stop the body from breaking DMT down. Lab studies and a small…

Alkaloids: synthesis and pharmacology Forensic Toxicology and Drug Analysis Psychedelics and Drug Studies Ayahuasca MDMA
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.